De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Chiome Bioscience Beheer

Beheer criteriumcontroles 2/4

De CEO Chiome Bioscience's is Shigeru Kobayashi, benoemd in Feb2017, heeft een ambtstermijn van 7.67 jaar. bezit rechtstreeks 0.41% van de aandelen van het bedrijf, ter waarde ¥ 30.04M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.5 jaar en 4.1 jaar.

Belangrijke informatie

Shigeru Kobayashi

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	7.7yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	7.5yrs
Gemiddelde ambtstermijn bestuur	4.1yrs

Recente managementupdates

Recent updates

Is Chiome Bioscience (TSE:4583) Using Too Much Debt?

Jun 28

CEO

Shigeru Kobayashi (71 yo)

7.7yrs

Tenure

Mr. Shigeru Kobayashi, M.E., has been Chief Executive Officer and President at Chiome Bioscience Inc. since February 18, 2017. Mr. Kobayashi has been an Executive Director of Business Planning and Developm...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Shigeru Kobayashi	CEO, President & Executive Director	7.7yrs	geen gegevens	0.41% ¥ 26.8m
Arihiko Bijohira	CFO, Head of Corporate Planning Officer & Executive Director	7.5yrs	geen gegevens	0.072% ¥ 4.7m
Ryuji Osawa	Head of Business Development and Executive Officer	8.8yrs	geen gegevens	geen gegevens
Teruyo Taoka	GM of Development Division & Director	4.3yrs	geen gegevens	0.038% ¥ 2.5m
Masamichi Koike	Head of Research Division & Executive Director	1.8yrs	geen gegevens	0.021% ¥ 1.4m

7.5yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4583 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shigeru Kobayashi	CEO, President & Executive Director	8.8yrs	geen gegevens	0.41% ¥ 26.8m
Arihiko Bijohira	CFO, Head of Corporate Planning Officer & Executive Director	7.5yrs	geen gegevens	0.072% ¥ 4.7m
Teruyo Taoka	GM of Development Division & Director	1.6yrs	geen gegevens	0.038% ¥ 2.5m
Masamichi Koike	Head of Research Division & Executive Director	1.6yrs	geen gegevens	0.021% ¥ 1.4m
Yoshiyuki Yamakawa	Audit & Supervisory Board Member	4.6yrs	geen gegevens	geen gegevens
Akiyuki Furuya	Audit & Supervisory Board Member	no data	geen gegevens	0.021% ¥ 1.4m
Haruhisa Kubota	Independent Outside Director	no data	geen gegevens	geen gegevens
Niro Sakamoto	Audit & Supervisory Board Member	3.6yrs	geen gegevens	geen gegevens

4.1yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4583 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Chiome Bioscience Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2024

Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2023

No independent directors

No independent directors

Chiome Bioscience Inc., Annual General Meeting, Mar 25, 2022

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2021

Recent updates

Second quarter 2024 earnings released: JP¥4.63 loss per share (vs JP¥9.00 loss in 2Q 2023)

Chiome Bioscience Inc. to Report Q3, 2024 Results on Nov 12, 2024

Is Chiome Bioscience (TSE:4583) Using Too Much Debt?

Chiome Bioscience Inc. to Report Q2, 2024 Results on Aug 13, 2024

Chiome Bioscience Inc. to Report Q1, 2024 Results on May 14, 2024

Full year 2023 earnings released: JP¥24.13 loss per share (vs JP¥28.26 loss in FY 2022)

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2024

Chiome Bioscience Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: JP¥5.25 loss per share (vs JP¥5.79 loss in 3Q 2022)

Chiome Bioscience Inc. to Report Q3, 2023 Results on Nov 14, 2023

Chiome Bioscience Inc. announced that it expects to receive ¥13.49304 million in funding

Chiome Bioscience Inc. to Report Q2, 2023 Results on Aug 09, 2023

Full year 2022 earnings released: JP¥28.26 loss per share (vs JP¥36.74 loss in FY 2021)

Chiome Bioscience Inc., Annual General Meeting, Mar 28, 2023

Chiome Bioscience Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: JP¥5.96 loss per share (vs JP¥10.77 loss in 3Q 2021)

No independent directors

Chiome Bioscience Inc. to Report Q3, 2022 Results on Nov 14, 2022

First half 2022 earnings released: JP¥18.17 loss per share (vs JP¥10.16 loss in 1H 2021)

Chiome Bioscience Inc. Announces First Patient in of Cancer Therapeutic Antibody CBA-1535 in A Phase 1 Clinical Trial

Chiome Bioscience Inc. Announces Conclusion of Contract with Additional Institutes and First Dosing of CBA-1205 in the Second Part of Phase 1 Study

Chiome Bioscience Inc. to Report Q2, 2022 Results on Aug 10, 2022

No independent directors

Chiome Bioscience Inc. to Report Q1, 2022 Results on May 13, 2022

Chiome Bioscience Inc. Submits an Initial Application for Phase I Study on CBA-1535

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chiome Bioscience Inc., Annual General Meeting, Mar 25, 2022

Chiome Bioscience Inc. Announces Move to the Second Half Part of Phase 1 Clinical Trial of First-In-Class CBA-1205

Chiome Bioscience Inc. announced that it has received ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm

Chiome Bioscience Inc. announced that it expects to receive ¥16.8 million in funding from SMBC Nikko Securities Inc., Investment Arm

Second quarter 2021 earnings released: JP¥6.16 loss per share (vs JP¥9.25 loss in 2Q 2020)

First quarter 2021 earnings released: JP¥4.07 loss per share (vs JP¥12.78 loss in 1Q 2020)

Chiome Bioscience Inc., Annual General Meeting, Mar 26, 2021

Chiome Bioscience Inc. to Report Fiscal Year 2020 Results on Feb 09, 2021

Shanghai Henlius Biotech, Inc. Enters into Exclusive License Agreement with Chiome Bioscience Inc. for Development and Commercialization of the Anti-Tpor-2 Antibodies, Liv-2008/2008B

New 90-day high: JP¥241

New 90-day low: JP¥203

Chiome Bioscience Inc. Announces Amendment to the License Agreement with ADC Therapeutics

Chiome Bioscience Inc. to Report Q3, 2020 Results on Nov 10, 2020

Chiome Bioscience Inc. to Report Q2, 2020 Results on Aug 11, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd